12 Health Care Stocks Moving In Monday's Intraday Session
Portfolio Pulse from Benzinga Insights
Health care stocks experienced significant movement in Monday's intraday session. Atreca, Cyclo Therapeutics, Elevation Oncology, Y-mAbs Therapeutics, Cadrenal Therapeutics, and ASLAN Pharma saw their stocks rise, with Atreca leading at a 52.7% increase. Conversely, MAIA Biotechnology, Sonoma Pharmaceuticals, Ekso Bionics Holdings, Avalo Therapeutics, Cyclacel Pharmaceuticals, and Venus Concept saw their stocks decline, with MAIA Biotechnology dropping by 22%.
January 15, 2024 | 5:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Avalo Therapeutics' stock dropped 15.43% to $5.81, with a market cap of $4.6 million.
The stock's decline may continue if the negative trend persists, potentially leading to further short-term losses.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
NEGATIVE IMPACT
Cyclacel Pharmaceuticals' shares fell 15.11% to $2.36, with a market cap of $2.4 million.
The negative movement in stock price could lead to further short-term depreciation if investor sentiment remains low.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
NEGATIVE IMPACT
Ekso Bionics Holdings' stock fell by 16.51% to $1.67, with a market cap of $23.7 million.
The decline in stock price could signal underlying issues or negative market sentiment, possibly leading to further short-term decreases.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
MAIA Biotechnology's shares declined by 22.0% to $1.1, with a market cap of $18.6 million.
The significant drop in stock price could reflect negative sentiment or events, likely leading to further short-term declines.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Sonoma Pharmaceuticals' stock decreased by 20.86% to $0.18, with a market cap of $2.5 million.
The drop in price may cause investor caution, potentially leading to further short-term selling pressure.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Venus Concept's stock fell 14.5% to $1.18, with a market cap of $6.5 million.
The stock's fall could be indicative of negative investor sentiment, which may result in further short-term losses.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
ASLAN Pharma's shares rose 19.21% to $0.94, with a market cap of $15.7 million.
The stock's rise could continue to draw attention from investors, potentially leading to further short-term increases.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
Atreca's stock rose 52.7% to $0.36, with a market cap of $14.1 million.
The substantial rise in stock price indicates a positive market reaction that could attract more investors in the short term, potentially maintaining the upward momentum.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Cadrenal Therapeutics' stock rose 22.46% to $0.75, with a market cap of $9.7 million.
The sharp increase in price may lead to short-term speculative interest, which could drive the price up further.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
Cyclo Therapeutics' shares increased by 29.51% to $1.86, with a market cap of $53.3 million.
The significant rise in share price could lead to continued investor interest in the short term, possibly driving the price further up.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Elevation Oncology's stock increased by 27.35% to $2.7, with a market cap of $114.5 million.
The stock's upward movement suggests a bullish outlook that may persist in the short term, potentially leading to further gains.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Y-mAbs Therapeutics' shares increased by 27.29% to $9.59, with a market cap of $418.1 million.
The notable increase in stock price could attract further interest from investors, potentially leading to more short-term gains.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100